

**CLINICAL RESEARCH TRIAL WITH RIGOSERTIB (ON 01910.Na) –  
NOW ENROLLING NCT01241500**

We would like to announce a clinical trial study for Myelodysplastic Syndrome (MDS ) patients who have relapsed after, become refractory to or intolerant to Vidaza® (azacitidine) or Dacogen® (decitabine) treatment.

The accrual of patients is ongoing for the rigosertib (ON 01910.NA) trial in myelodysplastic syndrome (ONTIME) clinical trial **NCT01241500**.

The primary purpose of this study is to compare overall survival (OS) in patients receiving rigosertib plus best supportive care (BSC) to OS of patients receiving BSC in a population of patients with MDS with excess blasts (5% to 30% bone marrow blasts) having failed, being intolerant, or relapsing after azacitidine or decitabine treatment.

Rigosertib is an investigational agent being evaluated for MDS, other blood malignancies and solid tumors. Patients in both the rigosertib arm and the control arm will be monitored closely throughout the trial and hospital stays are not required.

In an effort to accelerate the clinical development of rigosertib for myelodysplastic syndromes the MDS Foundation will be assisting the sponsor and would appreciate hearing from you.

If you are a physician or health care provider and would like to refer a patient for enrollment into this clinical trial OR if you are an MDS patient who has failed, become intolerant, or relapsed after Vidaza® (azacitidine) or Dacogen® (decitabine) treatment, please call the ONTIME Trial Help Line at 1-855-609-6564.

Virginia G. Piper Cancer Center Scottsdale, AZ PI: Mahesh Seetharama, MD	Lake County Oncology & Hematology Tavares, FL PI: Maen A. Hussein, MD	Dana-Farber Cancer Institute Boston, MA PI: David Steensma, MD	Medical Univ. of South Carolina Charleston, SC PI: Robert K. Stuart, MD
Desert Hematology Oncology Rancho Mirage, CA PI: David Young, MD	University of Chicago Med. Ctr. Chicago, IL PI: Lucy Godley, MD	Univ. of Michigan Cancer Center Ann Arbor, MI PI: Dale Bixby, MD, PhD	Bon Secours St. Francis Health Greenville, SC PI: Gary Spitzer, MD
Stanford Cancer Center Palo Alto, CA PI: Peter Greenberg, MD	Rush University Med. Ctr. Chicago, IL PI: Jamile Shammo, MD	Mayo Clinic Rochester, MN PI: Aref Al-Kali, MD	Univ. Of Texas – MD Anderson Cancer Ctr. Houston, TX PI: Guillermo Garcia- Manero, MD
Aventura Healthcare Associates Aventura, FL PI: Enrique Davila, MD	Edward Kaplan MD & Assoc. Skokie, IL PI: Marlon Kleinman, MD	St. Louis Cancer Center St. Louis, MO PI: Mark J. Fesler, MD	Cancer Centers of South Texas San Antonio, TX PI: Roger Lyons, MD
Integrated Community Oncology Jacksonville, FL PI: Lisa Reale, MD	Mary Bird Perkins Cancer Ctr. Baton Rouge, LA PI: Bryan Bienvenu, MD	Hackensack Univ. Med. Ctr. Hackensack, NJ PI: Stuart Goldberg, MD	St. Mary's Medical Ctr. Huntington, WV PI: Arvinder Bir, MD
Mount Sinai Cancer Centers Miami Beach, FL PI: Jose Lutzky, MD	Univ. of Maryland Greenbaum Cancer Center Baltimore, MD PI: Maria Baer, MD	Weill Cornell Medical College New York, NY PI: Gail Roboz, MD	
Martin Memorial Cancer Center Stuart, FL PI: Guiellermo Abesada-Terk, MD	Johns Hopkins Hospital Baltimore, MD PI: Steven D. Gore, MD	Cleveland Clinic Cleveland, OH PI: Mikkael Sekeres, MD	